Physician profile
Matthew C Holtzman
NPI 1275741647
$1,370,465.12
in general payments reported to CMS, 2019-2025
98 companies · $70K in 2025
The $70K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $243K · 2020: $152K · 2021: $296K · 2022: $287K · 2023: $187K · 2024: $136K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225K · Travel and Lodging: $61K · Honoraria: $59K · Food and Beverage: $24K · Consulting Fee: $23K · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $224,749.50 |
| Travel and Lodging | $61,411.98 |
| Honoraria | $59,125.00 |
| Food and Beverage | $24,389.30 |
| Consulting Fee | $23,247.50 |
| Education | $340.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530,566.61 | 2019-2025 | |
| Eisai INC. | $252,615.93 | 2019-2023 | |
| Sk Life Science, INC. | $96,824.83 | 2020-2025 | Xcopri |
| Allergan, INC. | $55,384.77 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $51,348.95 | 2020-2025 | Fycompa, Firdapse |
| Grifols USA, LLC | $49,936.92 | 2019-2024 | Gamunex-C |
| Medtronic Vascular, INC. | $48,209.17 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $46,633.02 | 2020-2021 | |
| Genentech USA, INC. | $38,972.54 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $23,194.53 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acorda Therapeutics, INC | $23,055.01 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22,946.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21,443.50 | 2020-2023 | |
| Celgene Corporation | $19,930.85 | 2020-2024 | Zeposia |
| Medtronic, INC. | $13,940.75 | 2021-2024 | Linq II |
Show all 96 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,333.76 | 2021-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $11,052.30 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $7,628.01 | 2019-2023 | Qelbree |
| Lundbeck LLC | $6,402.22 | 2019-2025 | Vyepti, Rexulti |
| Livanova USA, INC. | $5,968.25 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $5,580.37 | 2019-2025 | Nuplazid, Daybue |
| Mallinckrodt Enterprises LLC | $3,463.79 | 2019 | |
| Bausch Health US, LLC | $2,787.01 | 2019-2024 | Aplenzin, Wellbutrin |
| Genentech, INC. | $1,821.50 | 2021-2025 | Ocrevus, Enspryng |
| Abbott Laboratories | $1,739.49 | 2020-2021 | |
| F. Hoffmann-La Roche Ag | $1,200.00 | 2021 | |
| Ucb, INC. | $1,050.77 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Ipsen Biopharmaceuticals, INC | $902.01 | 2019-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $828.51 | 2019-2025 | |
| Genzyme Corporation | $821.23 | 2019-2025 | |
| Amgen INC. | $720.34 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $575.63 | 2019-2025 | Ultomiris, Soliris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $573.24 | 2020-2025 | Caplyta |
| Argenx US, INC. | $513.27 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $512.92 | 2022-2025 | Hyqvia, Gammagard |
| Emd Serono, INC. | $498.68 | 2019-2023 | Mavenclad |
| Biogen, INC. | $496.96 | 2020-2025 | Tysabri, Skyclarys, Skyclarys |
| Astrazeneca Pharmaceuticals Lp | $477.53 | 2021-2025 | Wainua |
| Csl Behring | $468.06 | 2019-2025 | Hizentra |
| Neurelis, INC. | $465.30 | 2020-2023 | Valtoco |
| Amneal Pharmaceuticals LLC | $449.79 | 2020-2024 | Rytary |
| Tg Therapeutics, INC. | $412.70 | 2022-2023 | |
| Tanabe Pharma America, INC. | $362.10 | 2019-2025 | Radicava |
| Neurocrine Biosciences, INC. | $361.10 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $358.62 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Axsome Therapeutics, INC. | $330.60 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Pfizer INC. | $315.74 | 2019-2025 | |
| Integra Lifesciences Corporation | $300.69 | 2022 | |
| Upsher-Smith Laboratories LLC | $272.41 | 2020-2023 | |
| Harmony Biosciences LLC | $254.23 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $249.59 | 2021-2025 | Spravato |
| Alnylam Pharmaceuticals INC. | $204.75 | 2019-2022 | |
| Mdd US Operations, LLC | $174.38 | 2019 | |
| Endo Pharmaceuticals INC. | $170.90 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $169.90 | 2022-2024 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $159.45 | 2019 | |
| Merz North America, INC. | $149.70 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $144.97 | 2020-2022 | |
| Nevro Corp. | $132.56 | 2023 | Senza |
| Zyla Life Sciences, INC. | $119.28 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $100.37 | 2023 | Aptiom |
| Vertical Pharmaceuticals, LLC | $90.76 | 2019-2020 | |
| Assertio Therapeutics, INC. | $88.98 | 2020 | |
| Greenwich Biosciences, INC. | $88.02 | 2019-2021 | |
| Promius Pharma LLC | $76.33 | 2019 | |
| Revance Therapeutics, INC. | $69.37 | 2024 | Daxxify |
| Aucta Pharmaceuticals, INC. | $65.79 | 2024-2025 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $64.50 | 2024-2025 | Horizant |
| Kyowa Kirin, INC. | $63.04 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $62.94 | 2019-2023 | Ztlido |
| Aprecia Pharmaceuticals, LLC | $56.08 | 2019-2022 | |
| Octapharma USA, INC. | $49.39 | 2023-2025 | Panzyga |
| Otsuka America Pharmaceutical, INC. | $44.38 | 2021-2022 | |
| Boston Scientific Corporation | $43.75 | 2025 | General - Dbs |
| Saol Therapeutics INC. | $43.25 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $41.00 | 2025 | Keveyis |
| Orphalan INC | $37.70 | 2023 | Cuvrior |
| Springworks Therapeutics, INC. | $34.00 | 2025 | Gomekli |
| Avion Pharmaceuticals | $31.10 | 2023 | Dhivy |
| Vanda Pharmaceuticals INC. | $30.80 | 2024 | Ponvory, Hetlioz, Fanapt |
| Janssen Biotech, INC. | $29.81 | 2025 | |
| Akcea Therapeutics, INC. | $27.78 | 2019 | |
| Alfasigma USA, INC. | $27.70 | 2021-2022 | |
| Hospira, INC. | $25.78 | 2025 | |
| Collegium Pharmaceutical, INC. | $24.44 | 2022 | |
| Corium, LLC | $22.03 | 2023 | Adlarity |
| Cycle Pharmaceuticals INC | $20.79 | 2025 | Tascenso Odt, Bafiertam |
| Bio Products Laboratory USA, INC. | $19.73 | 2023 | Coagadex, Gammaplex |
| Aquestive Therapeutics, INC. | $19.41 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $18.54 | 2023 | Relyvrio |
| Idorsia Pharmaceuticals US INC | $14.66 | 2024 | Quviviq |
| Forte Bio-Pharma LLC | $14.30 | 2024 | Prolate, Nalocet |
| Medtronic USA, INC. | $13.69 | 2019 | |
| Grt US Holding, INC. | $13.38 | 2021 | |
| Currax Pharmaceuticals LLC | $12.15 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,684.40 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Holtzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.